Despite ongoing challenges, as research deepens and treatment strategies continue to be optimized, selective RET inhibitors hold promise to drive RET-altered thyroid cancer treatment into a new era of greater precision and efficacy, ultimately resulting in improved treatment outcomes and quality of life for patients. The gene discussed is RET; the disease is thyroid gland carcinoma.